West Pharmaceutical Services Free Cash Flow (FCF) History (WST)
West Pharmaceutical Services reported $468.9M in free cash flow for fiscal 2025, an increase of 69.65% from the previous fiscal year, with a free cash flow margin of 15.25%.
View full West Pharmaceutical Services company overviewWest Pharmaceutical Services free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | $468.9M | $192.5M | +69.65% | +15.25% |
| 2024 | 2024-12-31 | $276.4M | −$138.1M | −33.32% | +9.55% |
| 2023 | 2023-12-31 | $414.5M | −$24.9M | −5.67% | +14.05% |
| 2022 | 2022-12-31 | $439.4M | $108.8M | +32.91% | +15.22% |
| 2021 | 2021-12-31 | $330.6M | $32.5M | +10.90% | +11.68% |
| 2020 | 2020-12-31 | $298.1M | $57.3M | +23.80% | +13.89% |
| 2019 | 2019-12-31 | $240.8M | $56.9M | +30.94% | +13.09% |
| 2018 | 2018-12-31 | $183.9M | $51.4M | +38.79% | +10.71% |
| 2017 | 2017-12-31 | $132.5M | $83.3M | +169.31% | +8.29% |
| 2016 | 2016-12-31 | $49.2M | −$31.6M | −39.11% | +3.26% |
| 2015 | 2015-12-31 | $80.8M | $9.8M | +13.80% | +5.77% |
| 2014 | 2014-12-31 | $71.0M | $2.4M | +3.50% | +5.00% |
| 2013 | 2013-12-31 | $68.6M | $12.5M | +22.28% | +5.01% |
| 2012 | 2012-12-31 | $56.1M | $20.8M | +58.92% | +4.43% |
| 2011 | 2011-12-31 | $35.3M | −$31.9M | −47.47% | +2.96% |
| 2010 | 2010-12-31 | $67.2M | $34.4M | +104.88% | +6.08% |
| 2009 | 2009-12-31 | $32.8M | $36.4M | — | +3.11% |
| 2008 | 2008-12-31 | −$3.6M | — | — | −0.34% |
West Pharmaceutical Services quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $80.8M | −$21.1M | −20.71% | +9.26% |
| Q1 2026 | 2026-03-31 | $47.2M | −$10.9M | −18.76% | +5.59% |
| Q4 2025 | 2025-12-31 | $175.0M | $89.8M | +105.40% | +21.74% |
| Q3 2025 | 2025-09-30 | $133.9M | $35.1M | +35.53% | +16.64% |
| Q2 2025 | 2025-06-30 | $101.9M | $37.1M | +57.25% | +13.29% |
| Q1 2025 | 2025-03-31 | $58.1M | $30.5M | +110.51% | +8.32% |
| Q4 2024 | 2024-12-31 | $85.2M | −$45.2M | −34.66% | +11.38% |
| Q3 2024 | 2024-09-30 | $98.8M | −$35.5M | −26.43% | +13.23% |
| Q2 2024 | 2024-06-30 | $64.8M | −$29.0M | −30.92% | +9.23% |
| Q1 2024 | 2024-03-31 | $27.6M | −$28.4M | −50.71% | +3.97% |
| Q4 2023 | 2023-12-31 | $130.4M | −$5.5M | −4.05% | +17.81% |
| Q3 2023 | 2023-09-30 | $134.3M | $23.2M | +20.88% | +17.97% |
| Q2 2023 | 2023-06-30 | $93.8M | −$13.2M | −12.34% | +12.44% |
| Q1 2023 | 2023-03-31 | $56.0M | −$29.4M | −34.43% | +7.81% |
| Q4 2022 | 2022-12-31 | $135.9M | $51.6M | +61.21% | +19.18% |
| Q3 2022 | 2022-09-30 | $111.1M | −$13.7M | −10.98% | +16.17% |
| Q2 2022 | 2022-06-30 | $107.0M | $19.5M | +22.29% | +13.87% |
| Q1 2022 | 2022-03-31 | $85.4M | $51.4M | +151.18% | +11.86% |
| Q4 2021 | 2021-12-31 | $84.3M | −$61.9M | −42.34% | +11.54% |
| Q3 2021 | 2021-09-30 | $124.8M | $53.7M | +75.53% | +17.66% |
| Q2 2021 | 2021-06-30 | $87.5M | −$23.5M | −21.17% | +12.09% |
| Q1 2021 | 2021-03-31 | $34.0M | $9.0M | +36.00% | +5.07% |
| Q4 2020 | 2020-12-31 | $146.2M | $77.4M | +112.50% | +25.20% |
| Q3 2020 | 2020-09-30 | $71.1M | −$5.3M | −6.94% | +12.97% |
| Q2 2020 | 2020-06-30 | $111.0M | $34.2M | +44.53% | +21.05% |
| Q1 2020 | 2020-03-31 | $25.0M | $6.2M | +32.98% | +5.09% |
| Q4 2019 | 2019-12-31 | $68.8M | $25.6M | +59.26% | +14.62% |
| Q3 2019 | 2019-09-30 | $76.4M | $14.5M | +23.42% | +16.75% |
| Q2 2019 | 2019-06-30 | $76.8M | $15.0M | +24.27% | +16.35% |
| Q1 2019 | 2019-03-31 | $18.8M | $1.8M | +10.59% | +4.24% |
| Q4 2018 | 2018-12-31 | $43.2M | −$8.8M | −16.92% | +10.22% |
| Q3 2018 | 2018-09-30 | $61.9M | $20.4M | +49.16% | +14.34% |
| Q2 2018 | 2018-06-30 | $61.8M | $6.0M | +10.75% | +13.81% |
| Q1 2018 | 2018-03-31 | $17.0M | $33.8M | — | +4.09% |
| Q4 2017 | 2017-12-31 | $52.0M | $27.7M | +113.99% | +12.51% |
| Q3 2017 | 2017-09-30 | $41.5M | $21.8M | +110.66% | +10.42% |
| Q2 2017 | 2017-06-30 | $55.8M | $14.6M | +35.44% | +14.03% |
| Q1 2017 | 2017-03-31 | −$16.8M | $19.2M | — | −4.33% |
| Q4 2016 | 2016-12-31 | $24.3M | $1.1M | +4.74% | +6.36% |
| Q3 2016 | 2016-09-30 | $19.7M | −$19.4M | −49.62% | +5.23% |
| Q2 2016 | 2016-06-30 | $41.2M | −$9.6M | −18.90% | +10.62% |
| Q1 2016 | 2016-03-31 | −$36.0M | −$3.7M | — | −9.94% |
| Q4 2015 | 2015-12-31 | $23.2M | $4.3M | +22.75% | +6.45% |
| Q3 2015 | 2015-09-30 | $39.1M | $3.8M | +10.76% | +11.35% |
| Q2 2015 | 2015-06-30 | $50.8M | $11.1M | +27.96% | +14.12% |
| Q1 2015 | 2015-03-31 | −$32.3M | −$9.4M | — | −9.62% |
| Q4 2014 | 2014-12-31 | $18.9M | −$11.1M | −37.00% | +5.40% |
| Q3 2014 | 2014-09-30 | $35.3M | $11.3M | +47.08% | +9.92% |
| Q2 2014 | 2014-06-30 | $39.7M | −$17.7M | −30.84% | +10.76% |
| Q1 2014 | 2014-03-31 | −$22.9M | $19.9M | — | −6.60% |
| Q4 2013 | 2013-12-31 | $30.0M | −$6.9M | −18.70% | +8.75% |
| Q3 2013 | 2013-09-30 | $24.0M | $1.4M | +6.19% | +7.02% |
| Q2 2013 | 2013-06-30 | $57.4M | $42.2M | +277.63% | +16.66% |
| Q1 2013 | 2013-03-31 | −$42.8M | −$24.2M | — | −12.61% |
| Q4 2012 | 2012-12-31 | $36.9M | $28.5M | +339.29% | +11.48% |
| Q3 2012 | 2012-09-30 | $22.6M | $7.1M | +45.81% | +7.44% |
| Q2 2012 | 2012-06-30 | $15.2M | −$6.1M | −28.64% | +4.68% |
| Q1 2012 | 2012-03-31 | −$18.6M | −$8.7M | — | −5.88% |
| Q4 2011 | 2011-12-31 | $8.4M | −$17.5M | −67.57% | +2.84% |
| Q3 2011 | 2011-09-30 | $15.5M | −$15.3M | −49.68% | +5.28% |
| Q2 2011 | 2011-06-30 | $21.3M | $4.6M | +27.54% | +6.92% |
| Q1 2011 | 2011-03-31 | −$9.9M | −$3.7M | — | −3.35% |
| Q4 2010 | 2010-12-31 | $25.9M | — | — | +9.36% |
| Q3 2010 | 2010-09-30 | $30.8M | $19.4M | +170.18% | +11.35% |
| Q2 2010 | 2010-06-30 | $16.7M | — | — | +5.93% |
| Q1 2010 | 2010-03-31 | −$6.2M | — | — | −2.26% |
| Q3 2009 | 2009-09-30 | $11.4M | — | — | +4.40% |
West Pharmaceutical Services free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from $298.1M to $468.9M, a compound annual growth rate of 9.48%. West Pharmaceutical Services's latest reported quarter, Q2 2026, generated $80.8M in free cash flow, a decrease of 20.71% year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review West Pharmaceutical Services source filings ↗